Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Less can be more in endocarditis treatment. The POET II trial found that tailoring antibiotic duration to patient response — cutting treatment time by about one-third — met safety standards compared to the standard fixed-duration regimen. While relapse rates were slightly higher in the shorter-course group, most cases were manageable without surgery, suggesting personalized treatment could be a viable path forward for select patients.
The POET II trial is challenging a long-standing dogma in infectious disease: that infective endocarditis requires a fixed, lengthy course of antibiotics. Presented at the European Society of Cardiology Congress 2026 and simultaneously published in the New England Journal of Medicine, the trial found that stopping antibiotics early — once patients met strict clinical stabilization criteria — was non-inferior to standard therapy on key safety outcomes.
The trial enrolled 508 patients across 13 sites in Denmark, Sweden, and the US. Those in the response-tailored arm stopped antibiotics after a median of 26 days, compared to 41 days in the standard group — roughly one-third less treatment time. The primary safety endpoint (all-cause mortality, unplanned heart valve surgery, or symptomatic embolic events at 6 months) was 8.2% vs. 10.7%, meeting the noninferiority threshold.
Key Takeaways:
Why it matters: Shorter antibiotic courses could reduce drug side effects, hospital stays, antimicrobial resistance, and costs — while improving quality of life. Experts caution this approach should be reserved for selected patients at specialized centers.
